Skip to main content

Table 1 Demographic and clinical data of the MS patients and controls

From: Serum levels of leptin and adiponectin in patients with multiple sclerosis

  MS patients (N = 30) Controls (N = 30) Test of significance P
Age (years): Mean ± SD 31.03 ± 6.31 31.4 ± 7.5 0.36 0.71
Gender: N (%) 0.08 0.78
 Male 9 (30%) 10 (33.3%)
 Female 21 (70%) 20 (66.7%)
BMI (kg/m2) Mean ± SD 28.4 ± 7.2 26.7 ± 6.5 0.95 0.5
Serum leptin (pg/ml) Mean ± SD 14,963.96 ± 10,917.97 6389.61 ± 3473.51 20.7  < 0.001*
Serum adiponectin (ng/ml) Mean ± SD 4352 ± 1275 3995 ± 1088 1.17 0.24
MS types: N (%)
 RRMS 24 (80.0%) NA   
 SPMS 3 (10%)   
 PPMS 3 (10%)   
Patients in relapse N (%) 12 (40%) NA   
Onset of disease (years): Mean ± SD 27 ± 7.6 NA   
Duration of disease (years) Mean ± SD 3.7 ± 3.5 NA   
Total relapse number Mean ± SD 3.23 ± 1.63 NA   
ARR: Mean ± SD 1.08 ± 0.89 NA   
EDSS: Mean ± SD 2.17 ± 1.87 NA   
MSSS: Mean ± SD 3.84 ± 2.6 NA   
PI: mean ± SD 0.83 ± 0.9 NA   
  1. MS multiple sclerosis, RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, SD standard deviation, EDSS Expanded Disability Score, MSSS Multiple Sclerosis Severity Score, PI progression index, NA not applicable, *Significant